News
December 18, 2017: 
-BPL has signed an agreement with a global company (Fortune500) to collaborate in the development of a new protein-based drug candidate.
According to the agreement, BPL will develop a bacterial fermentation, refolding process,
purification and formulation as well as the related analytical testing methods.
For this project, BPL will  utilize its know-how and experience in recombinant protein expression in bacterial systems, purification and product formulation.
 

 November 2017
-BPL has signed an agreement with US based company for the development and production of series of enzymes and their immobilization to solid matrices. BPL will utilize its know-how and experience in recomninant enzyme expression in bacterial systems, purification and product formulation.



-BPL is relocating to a new facility in Yavne- 15 Nahal Snir st. The facility, designed and constructed specially according to BPL's plans and requirements, will be ready by ebd December 2017. BPL will start operation in the new facility by beginning January 2018.





 
 
Mailing List

Please enter your e-mail address

 Send

 
Share
 
FGF-2

The Fibroblast Growth Factors (FGFs) constitute a large family of proteins involved in many aspects of development including cell proliferation, growth, and differentiation. They act on several cell types to regulate diverse physiologic functions including angiogenesis, cell growth, pattern formation, embryonic development, metabolic regulation, cell migration, neurotrophic effects, and tissue repair. FGF family activities are mediated by receptor tyrosine kinases and are facilitated by heparan sulfate. Family members have been implicated in several disorders of bone growth, as well as in tumor formation and progression.
 
BPL Biologics     19 Hidekel st. Yavne POB 13240  8122614  Israel
Tel: +972.76.548.8118   US: +973.723.9000